Macrocyclic HCV Protease Inhibitors with Peptidomimetic Warheads
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hepatitis C virus (HCV) therapies face challenges such as limited efficacy, significant side effects, emergence of drug-resistant mutants, and compliance issues due to sub-optimal pharmacokinetics and complex dosage regimes, necessitating the development of more effective and better-tolerated treatments.
Innovation Solution
Development of macrocyclic compounds with inhibitory activity against HCV replication, specifically represented by formula (I), which offer good cell permeability and bioavailability, overcoming the limitations of existing protease inhibitors by providing an alternative mechanism of action.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current HCV therapies (interferon-alpha and ribavirin) are administered, then viral replication is inhibited, but significant side effects occur and efficacy is limited
Solution Approach 1:
The patent employs peptidomimetic structures that mimic the transition state of the HCV protease reaction, using modified peptide bonds and non-natural amino acid analogs to achieve high affinity binding while avoiding the immunogenicity and cytotoxicity of interferon-based therapies. The macrocyclic constraints and specific substituent patterns optimize pharmacokinetic properties to reduce side effects.
Solution Approach 2:
The invention replaces the immunomodulatory mechanism of interferon-alpha with a direct enzymatic inhibition mechanism using small molecule protease inhibitors. This substitution eliminates the need for complex immune system modulation and its associated side effects, providing a more targeted and tolerable therapeutic approach.
2Reliability
If peptidomimetic HCV protease inhibitors are administered, then viral protease activity is inhibited, but drug-resistant mutants emerge
Solution Approach 1:
The patent utilizes composite molecular structures combining peptidomimetic warheads with macrocyclic constraints and diverse substituent patterns. This composite design creates multiple interaction points with the protease active site, making it more difficult for the virus to develop resistance through single-point mutations compared to simpler peptide inhibitors.
Solution Approach 2:
The invention introduces specific local modifications at key positions within the inhibitor structure, including constrained cyclic structures and strategically placed hydrophobic or electrostatic interactions. These localized enhancements create a more rigid and specific binding mode that reduces the protease's ability to accommodate mutant variants.
3Reliability
If complex dosage regimes are implemented, then therapeutic effectiveness is maintained, but patient compliance deteriorates
Solution Approach 1:
The patent describes inhibitors with pharmacokinetic profiles that enable once-daily or less frequent dosing intervals. The molecular structures are designed to maintain stable plasma concentrations and sustained protease inhibition over extended periods, eliminating the need for complex multi-dose regimens and improving patient compliance.
Solution Approach 2:
The invention optimizes the dynamic properties of the inhibitors including metabolic stability, protein binding characteristics, and tissue distribution. These dynamic optimizations ensure that a single dose maintains therapeutic levels throughout the dosing interval, simplifying the treatment regimen while preserving effectiveness.
Data Source
AI summary
Inhibitors of HCV replication of formula (I), the N-oxides, salts, and stereochemically isomeric forms thereof, wherein each dashed line (represented by -------) represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is aryl or a saturated, a partially unsaturated or completely unsaturated 5 or 6 membered monocyclic or 9 to 12 membered bicyclic heterocyclic ring system wherein said ring system contains one nitrogen, and optionally one to three additional heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen, and wherein the remaining ring members are carbon atoms; wherein said ring system may be optionally substituted on any carbon or nitrogen ring atom with one, two, three, or four substituents; L is a direct bond, -O-. -O-C1-4alkanediyl-, -O-C(=O)-, -O-C(=O)-NR4a- or -O-C(=O)-NR4aC1-4alkanediyl-; R2 is hydrogen, -OR5, -C(O)OR5, -C(=O)R6, -C(=O)NR4aR4b, -C(=O)NHR4c,-NR4aR4b, -NHR4c, -NR4aSOpNR4aR4b, -NR4aSOpR7, or B(OR5)2; R3 is hydrogen, and where X is C or CH, R3 may also be C1-6alkyl; n is 3, 4, 5, or 6; p is 1 or 2; aryl is phenyl, naphthyl, indanyl, or 1,2,3,4-tetrahydronaphthyl, each of which may be optionally substituted with one, two or three substituents ; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms each independently selected from nitrogen, oxygen and sulfur, being optionally condensed with a benzene ring, and wherein the group Het as a whole may be optionally substituted with one, two or three substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.